Drugs / parthenolide
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07236190 | Apr 2026 → Jun 2027 expected | Alzheimer disease, subjective cognitive decline | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT00133341 | Apr → Dec 2005 | allergic contact dermatitis | Mekos Laboratories AS | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00640614 | Apr 2008 → Aug 2009 | contact dermatitis | Allerderm | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | parthenolide | “Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse...” NCT00640614 ↗ |
| Known as | NSC-157035 | ChEMBL registry synonym — accepted as the source's own label CHEMBL540445 ↗ |
| Modality | Small molecule | — CHEMBL540445 ↗ |